← BLACKLEDGER Content Feed

Buying • NEUROPHAGE x BLACKLEDGER • 9 min read • 2026-07-08

BLACKLEDGER Buying Watch: DELL, NET, VKTX

BLACKLEDGERMarket ResearchBuyingDELLNETVKTXNTLA
BLACKLEDGER Buying public market research update for DELL, NET, VKTX

BLACKLEDGER's latest buying watch update tracks DELL, NET, VKTX, NTLA, NEAR, TIA from the active public watchlist. This post is built from public-safe status data, in-house public signal labels, and outside public source context. It is designed to help readers understand what is happening around each asset without exposing private research methods.

Buying Watch Data

The dedicated feed category for this update is Buying. The latest public scan timestamp is 2026-07-08T08:00:10.948152+00:00.

Educational Context: How To Use This Page

This page is not a trade instruction. It is an educational research brief. Readers can use it to understand company or project background, public market context, public status labels, and relevant outside-source headlines before doing their own due diligence.

DELL Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Dell Technologies Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.

Dell Technologies Inc. designs, develops, manufactures, markets, sells, and supports various comprehensive and integrated solutions, products, and services in the Americas, Europe, the Middle East, Asia, and internationally. The company operates through Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG) segments. The ISG segment provides modern and traditional storage solutions, including all-flash, purpose-built, hyper-converged infrastructure, software-defined storage, and general-purpose and AI-optimized servers. This segment also offers networking products and services comprising wide area network infrastructure, data center and edge networking switches, and cables and optics that help its business customers to transform and modernize their infrastructure and complementing its server and storage solutions; and software, peripherals, and services, including consulting and support, and deployment. The CSG segment pr

Why DELL Is In This Public Update

Outside Public Headlines / Source Notes

NET Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Cloudflare, Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.

Cloudflare, Inc. operates as a cloud services provider that delivers a range of services to businesses worldwide. The company provides a cloud-based security solution to secure a range of combination of platforms, including public and private cloud, on-premises, software-as-a-service applications, and Internet of things (IoT) devices; and application security products comprising web application firewall, bot management, distributed denial of service mitigation, API security, SSL/TLS encryption, client-side security, and security center products. It also offers application performance solutions, such as content delivery, load balancing, DNS, [redacted]rt shield, video stream delivery, web optimization, cloudfare waiting room, and cloudfare data localization suite; SASE platform that combines network services and Zero Trust and workplace security products that provides a cloud-based network and security-as-a-service; network services, inc

Why NET Is In This Public Update

Outside Public Headlines / Source Notes

VKTX Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Viking Therapeutics, Inc.. Market class: stock. Public bias: Bull. Public tier: Extended.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystr

Why VKTX Is In This Public Update

Outside Public Headlines / Source Notes

NTLA Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: Intellia Therapeutics, Inc.. Market class: stock. Public bias: Bull. Public tier: A-List.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioed[redacted]. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeu

Why NTLA Is In This Public Update

Outside Public Headlines / Source Notes

NEAR Public Research Bio

Deep bio flag: This asset reached the 9+ public rating threshold, so BLACKLEDGER includes a fuller company/project profile, outside-source context, and public education notes.

Name: NEAR Protocol USD. Market class: crypto. Public bias: Bull. Public tier: A-List.

NEAR Protocol (NEAR) is a cryptocurrency launched in 2020. NEAR Protocol has a current supply of 1,293,447,018. The last known price of NEAR Protocol is 1.36849788 USD and is up 0.87 over the last 24 hours. It is currently trading on 631 active market(s) with $176,250,290.27 traded over the last 24 hours. More information can be found at https://near.org/.

Why NEAR Is In This Public Update

Outside Public Headlines / Source Notes

TIA Public Research Bio

Name: Celestia USD. Market class: crypto. Public bias: Bull. Public tier: A-List.

Celestia (TIA) is a cryptocurrency launched in 2023and operates on the Osmosis platform. Celestia has a current supply of 1,168,685,161.483695 with 919,932,996.62251 in circulation. The last known price of Celestia is 0.38987291 USD and is up 3.03 over the last 24 hours. It is currently trading on 358 active market(s) with $30,680,638.37 traded over the last 24 hours. More information can be found at https://www.celestia.org.

Why TIA Is In This Public Update

Outside Public Headlines / Source Notes

What The Public Data Shows

The public feed highlights ticker status, market class, directional bias, score, tier, confidence, company or project profile, public market references, and outside-source headlines. These fields support a deeper view of BLACKLEDGER's public research feed while keeping private methods undisclosed.

Why This Category Matters

The Buying section gives readers a focused path through the market: buying watch content for constructive candidates, selling watch content for defensive movement, investing content for higher-quality public watch names, and market trend notes for broader context.

Research-Only Notice

BLACKLEDGER content is market research only. There is no live execution signal, no recommendation to buy or sell, and no financial advice. Readers should perform their own due diligence and consult licensed professionals before making financial decisions.

Research-only. No execution signal. Not financial advice.